研究者
J-GLOBAL ID:202001016447270374   更新日: 2024年12月10日

徳田 深作

トクダ シンサク | Tokuda Shinsaku
所属機関・部署:
職名: 講師
競争的資金等の研究課題 (1件):
  • 2023 - 2026 肺がん低酸素環境適応機構に起因した治療抵抗性の解明と新規標的治療法開発
論文 (37件):
  • Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al. YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024
  • Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, et al. Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy. Thoracic cancer. 2024. 15. 26. 1882-1888
  • Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, et al. CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Translational lung cancer research. 2024. 13. 8. 1929-1937
  • Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer letters. 2024. 598. 217124-217124
  • Yohei Matsui, Tadaaki Yamada, Yuki Katayama, Soichi Hirai, Ryo Sawada, Yusuke Tachibana, Masaki Ishida, Hayato Kawachi, Ryota Nakamura, Naoya Nishioka, et al. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer science. 2024
もっと見る
学位 (1件):
  • 医学博士 (神戸大学大学院医学研究科)
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る